| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ... Nature medicine 27 (3), 504-514, 2021 | 473 | 2021 |
| Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer JP Robichaux, YY Elamin, Z Tan, BW Carter, S Zhang, S Liu, S Li, T Chen, ... Nature medicine 24 (5), 638-646, 2018 | 455 | 2018 |
| Safety of programmed Death–1 pathway inhibitors among patients with Non–Small-Cell lung cancer and preexisting autoimmune disorders GC Leonardi, JF Gainor, M Altan, S Kravets, SE Dahlberg, L Gedmintas, ... Journal of Clinical Oncology 36 (19), 1905, 2018 | 313 | 2018 |
| Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression EJ Aguilar, B Ricciuti, JF Gainor, KL Kehl, S Kravets, S Dahlberg, ... Annals of Oncology 30 (10), 1653-1659, 2019 | 289 | 2019 |
| Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11-and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status B Ricciuti, KC Arbour, JJ Lin, A Vajdi, N Vokes, L Hong, J Zhang, ... Journal of Thoracic Oncology 17 (3), 399-410, 2022 | 200 | 2022 |
| Differential expression and significance of PD-L1, IDO-1, and B7-H4 in human lung cancer KA Schalper, D Carvajal-Hausdorf, J McLaughlin, M Altan, V Velcheti, ... Clinical Cancer Research 23 (2), 370-378, 2017 | 190 | 2017 |
| Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial J Welsh, H Menon, D Chen, V Verma, C Tang, M Altan, K Hess, ... Journal for immunotherapy of cancer 8 (2), 2020 | 187 | 2020 |
| Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis H Abu-Sbeih, FS Ali, X Wang, N Mallepally, E Chen, M Altan, RS Bresalier, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 154 | 2019 |
| Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC L Hong, MV Negrao, SS Dibaj, R Chen, A Reuben, JM Bohac, X Liu, ... Journal of Thoracic Oncology 15 (9), 1449-1459, 2020 | 142 | 2020 |
| Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) D Carvajal-Hausdorf, M Altan, V Velcheti, SN Gettinger, RS Herbst, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 141 | 2019 |
| Role of radiation therapy in modulation of the tumor stroma and microenvironment H Menon, R Ramapriyan, TR Cushman, V Verma, HH Kim, ... Frontiers in immunology 10, 193, 2019 | 135 | 2019 |
| Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC MM Awad, SM Gadgeel, H Borghaei, A Patnaik, JCH Yang, SF Powell, ... Journal of Thoracic Oncology 16 (1), 162-168, 2021 | 129 | 2021 |
| Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC SH Lin, Y Lin, L Yao, N Kalhor, BW Carter, M Altan, G Blumenschein, ... Journal of Thoracic Oncology 15 (2), 248-257, 2020 | 123 | 2020 |
| Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance V Pelekanou, DE Carvajal-Hausdorf, M Altan, B Wasserman, ... Breast Cancer Research 19, 1-11, 2017 | 120 | 2017 |
| OA02. 06 a phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC) J Heymach, M Negrao, J Robichaux, B Carter, A Patel, M Altan, ... Journal of Thoracic Oncology 13 (10), S323-S324, 2018 | 119 | 2018 |
| OA02. 06 a phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC) J Heymach, M Negrao, J Robichaux, B Carter, A Patel, M Altan, ... Journal of Thoracic Oncology 13 (10), S323-S324, 2018 | 119 | 2018 |
| B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes M Altan, V Pelekanou, KA Schalper, M Toki, P Gaule, K Syrigos, ... Clinical Cancer Research 23 (17), 5202-5209, 2017 | 118 | 2017 |
| Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury H Abu-Sbeih, T Tang, Y Lu, S Thirumurthi, M Altan, AA Jazaeri, R Dadu, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 115 | 2019 |
| Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy H Menon, D Chen, R Ramapriyan, V Verma, HB Barsoumian, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 112 | 2019 |
| Immune checkpoint inhibitor–associated pericarditis M Altan, MI Toki, SN Gettinger, DE Carvajal-Hausdorf, J Zugazagoitia, ... Journal of Thoracic Oncology 14 (6), 1102-1108, 2019 | 92 | 2019 |
